Antithrombotic therapy in peripheral arterial occlusive disease

Chest

Volumn 119, Issue 1 SUPPL., 2001, Pages 283S-299S

  Jackson, M R ^a   Clagett, G P ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANTICOAGULANT AGENT; CILOSTAZOL; CLOPIDOGREL; DEXTRAN 40; DIPYRIDAMOLE; ECRAPROST; EDETIC ACID; FISH OIL; HEPARIN; KETANSERIN; LOW MOLECULAR WEIGHT HEPARIN; NAFTIDROFURYL; NIFEDIPINE; PENTOXIFYLLINE; PICOTAMIDE; PROSTACYCLIN; PROSTAGLANDIN E1 DERIVATIVE; SEROTONIN ANTAGONIST; STREPTOKINASE; SULOCTIDIL; TICLOPIDINE; UNCLASSIFIED DRUG; UROKINASE; WARFARIN;

ANTICOAGULANT THERAPY; ARTERY PROSTHESIS; ARTERY RECONSTRUCTION; ATHEROSCLEROSIS; BLEEDING; CAROTID ENDARTERECTOMY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM FUNCTION DISORDER; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HEADACHE AND FACIAL PAIN; HEMATOMA; HUMAN; META ANALYSIS; MULTICENTER STUDY; NEUTROPENIA; PATHOGENESIS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOGENESIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; VEIN GRAFT;

EID: 0035124252     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.119.1_suppl.283S     Document Type: Conference Paper

References (207)

1. Prevalence of intermittent claudication and its effect on mortally
2. Fate in intermittent claudication: Outcome and risk factors
3. Prevalence of symptomatic leg ischaemia in a Swedish community: An epidemiological study
4. The prevalence of peripheral arterial disease in a defined population
5. Ankle-arm index as a marker of atherosclerosis in the cardiovascular health study
6. Intermittent claudication: Its natural course
7. Intermittent claudication
8. Nonoperative treatment of superficial femoral artery disease: Long-term follow-up
9. Relationship of severity of lower limb peripheral vascular disease to mortality and morbidity: A six-year follow-up study
10. Non-invasively detected carotid stenosis and ischaemic heart disease in men with leg arteriosclerosis
11. Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease: A prospective double-blind arteriographically controlled trial
12. Low-dose aspirin and subsequent peripheral arterial surgery in the Physicians Health Study
13. Aspirin and other platelet-active drugs: The relationship between dose, effectiveness, and side effects
14. Can drugs help patients with lower limb ischaemia?
15. Intermittent claudication and rest pain: Physiologic concepts and therapeutic approaches
16. Obliterative arterial disease of the lower limbs: IV. Evaluation of long-term anticoagulant therapy
17. A double-blind trial of suloctidil vs placebo in intermittent claudication
18. Therapeutic effect of ticlopidine, a new inhibitor of platelet aggregation, on chronic arterial occlusive diseases, a double-blind study versus placebo
19. Ticlopidine in the treatment of peripheral occlusive arterial disease
20. Ticlopidine in the treatment of intermittent claudication: A 21-month doubleblind trial
21. Is it possible to reduce the risk of cardiovascular events in subjects suffering from intermittent claudication of the lower limbs?
22. Reduction of the requirement for leg vascular surgery during long-term treatment of claudicant patients with ticlopidine: Results from the Swedish Ticlopidine Multicentre Study (STIMS)
23. Thrombotic thrombocytopenic purpura associated with ticlopidine: A review of 60 cases
24. Secondary prevention of vascular disease by prolonged antiplatelet treatment
25. Collaborative overview of randomized trials of antiplatelet therapy: I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
26. The basic pharmacology of ticlopidine and clopidogrel
27. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
28. 1 infusions in occlusive arterial disease stage III/IV
29. 1 in the treatment of lower extremity ischemic ulcers secondary to peripheral vascular occlusive disease: Results of a prospective randomized, double-blind, multicenter clinical trial
30. Prostacyclin for ischemic ulcers in peripheral arterial disease: A random assignment, placebo controlled study
31. Epoprostenol (prostacyclin) and severe arterial disease: A double-blind study
32. Prostacyclin treatment of ischemic ulcers and rest pain in unreconstructible peripheral arterial occlusive disease
33. 1 or intravenous pentoxifylline during training
34. 1
35. 1 prodrug, in patients with intermittent claudication
36. Improvement of the flow properties of blood: A new therapeutical approach in occlusive arterial disease
37. Influence of pentoxifylline on erythrocyte deformability in peripheral occlusive arterial disease
38. Treatment of claudication with pentoxifylline: Are benefits related to improvement in viscosity?
39. Influence of risk factors and coagulation phenomena on the fluidity of blood in chronic arterial occlusive disease
40. Beneficial hemorheologic therapy of chronic peripheral arterial disorders with pentoxifylline: Results of double blind study versus vasodilator-nylidrin
41. Double blind study of pentoxifylline against placebo in patients with intermittent claudication
42. Placebo controlled double blind study with pentoxifylline of walking performance in patients with intermittent claudication
43. Trental 400 in the treatment of intermittent claudication: Results of long-term, placebo-controlled administration
44. Double-blind, crossover study of the clinical efficacy and the hemorheological effects of pentoxifyline in patients with occlusive arterial disease of the lower limbs
45. Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease
46. A comparison between aspirin and pentoxifylline in relieving claudication due to peripheral vascular disease in the elderly
47. Pentoxifylline efficacy in the treatment of intermittent claudication: Multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients
48. Acenocoumarol and pentoxifylline in intermittent claudication: A controlled clinical study; the APIC study group
49. Intermittent claudication: A double-blind crossover trial of pentoxifylline
50. Effects of flunarizine and pentoxifylline on walking distance and blood rheology in claudication
51. A controlled trial of pentoxifylline (Trental 400) in intermittent claudication: Clinical, haemostatic and rheological effects
52. Treatment of circulatory disturbances with pentoxifylline: A double blind study with Trental
53. Conservative management of intermittent claudication
54. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease
55. Cilostazol has beneficial effects in treatment of intermittent claudication: Results from a multicenter, randomized, prospective, double-blind trial
56. The effect of withdrawal of drugs treating intermittent claudication
57. A new pharmacologic treatment for intermittent claudication: Results of a randomized, multicenter trial
58. Randomized placebo-controlled, double-blind trial of ketanserin in claudicants: Changes in claudication distance and ankle systolic pressure
59. Controlled trial of suloctidil in intermittent claudication
60. The effect of nifedipine on calf blood flow and exercise capacity in patients with intermittent claudication
61. Fish oil supplementation in patients with stable claudication
62. A controlled trial of naftidrofuryl (Praxilene) in the treatment of intermittent claudication
63. Naftidrofuryl for ischaemic rest pain: A controlled trial
64. EDTA treatment of intermittent claudication: A double-blind, placebo-controlled study
65. Chelation therapy for intermittent claudication: A double-blind, randomized, controlled trial
66. Increases in walking distance in patients with peripheral vascular disease treated with L-carnitine: A double-blind, cross-over study
67. Effect of picotamide on the clinical progression of peripheral vascular disease: A double-blind placebo-controlled study
68. Effects of picotamide, an antithromboxane agent, on carotid atherosclerotic evolution: A two-year, double-blind, placebo-controlled study in diabetic patients
69. Vascular trauma secondary to diagnostic and therapeutic procedures: 1974 through 1982; a comparative review
70. Vascular complications of cardiac catheterization
71. Complex upper extremity vascular trauma in an urban population
72. Arterial embolization: Problems of source, multiplicity, recurrence, and delayed treatments
73. Arterial embolism: A 44-year perspective
74. Management of acute lower extremity arterial ischemia due to embolism and thrombosis
75. Differential management of acute peripheral arterial ischemia
76. Acute arterial thrombosis of the lower extremity: Its natural history contrasted with arterial embolism
77. Factors that affect the outcome of peripheral arterial embolization
78. Arterial thromboembolism
79. Peripheral arterial embolism: A 20-year review
80. Delayed arterial embolectomy: A new concept
81. Anticoagulant treatment during and after embolectomy
82. Arterial embolectomy before and after the Fogarty catheter
83. Heparin: Efficacy and safety after arterial operations
84. Peripheral arterial emboli and factors in their recurrence rate
85. Streptokinase: A review of its clinical pharmacology, mechanism of action and therapeutic uses
86. Outcome of recent thromboembolic occlusions of limb arteries treated with streptokinase
87. Selective clot lysis with low-dose streptokinase
88. Intra-arterial urokinase as the initial therapy for acutely ischemic lower limbs
89. Efficacy of thrombolysis in infrainguinal bypass grafts
90. Local low-dose thrombolytic therapy of peripheral arterial occlusions
91. Salvage of occluded arterial bypass grafts by means of thrombolysis
92. Regional infusion of urokinase into occluded lower-extremity bypass grafts: Long-term clinical results
93. Thrombolysis of peripheral arterial bypass grafts: Surgical thrombectomy compared with thrombolysis
94. Local thrombolysis in the treatment of arterial graft occlusions
95. A reevaluation of intraarterial thrombolytic therapy for acute lower extremity ischemia
96. Thrombolysis with tissueplasminogen activator: Results with a high-dose transthrombus technique
97. Thrombolysis in acute lower limb ischaemia
98. Use and limitations of thrombolytic therapy in the treatment of peripheral arterial ischemia: Results of a multi-institutional questionnaire
99. Randomized trial of intra-arterial recombinant tissue plasminogen activator, intravenous recombinant tissue plasminogen activator and intra-arterial streptokinase in peripheral arterial thrombolysis
100. Recombinant tissue-type plasminogen activator versus urokinase in peripheral arterial and graft occlusions: A randomized trial
101. Update on urokinase and streptokinase: A comparison of their efficacy and safety
102. Urokinase versus streptokinase in local thrombolysis
103. Surgical treatment versus thrombolysis in acute arterial occlusion: A randomised controlled study
104. A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia
105. Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity
106. Comparison of tissue plasminogen activator and urokinase in the local infiltration thrombolysis of peripheral arterial occlusions
107. Thrombolysis or peripheral arterial surgery: Phase I results; TOPAS Investigators
108. A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs
109. Local streptokinase infusion for superior mesenteric artery thromboembolism
110. Renal arteryembolism: Therapy with intra-arterial streptokinase infusion
111. The use of streptokinase to treat renal arterial thromboembolism
112. Thrombolysis in the management of lower limb peripheral arterial occlusion a consensus document
113. Intraoperative streptokinase: An adjunct to mechanical thrombectomy in the management of acute ischemia
114. Intraoperative fibrinolytic therapy: An adjunct to catheter thromboembolectomy
115. Intra-arterial thrombin activity produced by percutaneous transluminal angioplasty eliminated by segmentally enclosed thrombolysis
116. Role of intraoperative fibrinolytic therapy in acute arterial occlusion
117. Intraoperative, intraarterial thrombolytic therapy for salvage of limbs in patients with distal arterial thrombosis
118. Fibrinolytic treatment of residual thrombus after catheter embolectomy for severe lower limb ischemia
119. Isolated limb perfusion with urokinase for acute ischemia
120. A prospective, randomized, blinded, and placebo-controlled trial of intraoperative intra-arterial urokinase infusion during lower extremity revascularization: Regional and systemic effects
121. Six-year prospective multicenter randomized comparison of autologous saphenous vein and expanded polytetrafluoroethylene grafts in infrainguinal arterial reconstructions
122. Present status of reversed vein bypass grafting: Five-year results of a modern series
123. Prospective randomized multicenter comparison of in situ and reversed vein infrapopliteal bypasses
124. A randomized clinical trial of PTFE versus human umbilical vein for femoropopliteal bypass surgery: Preliminary results
125. PTFE or HUV for femoro-popliteal bypass: A multi-centre trial
126. Polytetrafluoroethylene versus human umbilical vein in above-knee femoropopliteal bypass: Six-year results of a randomized clinical trial
127. Pathophysiology of vein graft failure: A review
128. Biologic fate of autogenous vein implants as arterial substitutes: Clinical, angiographic and histopathologic observations in femoropopliteal operations for atherosclerosis
129. Antiplatelet therapy reduces aortic intimal hyperplasia distal to small-diameter vascular prostheses (PTFE) in nonhuman primates
130. Aspirin and dipyridamole decrease intimal hyperplasia in experimental vein grafts
131. Reduction of intimal thickening in canine coronary bypass vein grafts with dipyridamole and aspirin
132. Failure of certain antiplatelet drugs to affect myointimal thickening following arterial injury
133. Aspirin and dipyridamole inhibit endothelial healing
134. The role of aspirin in enhancing arterial graft patency
135. Role of platelets and platelet inhibitors in aortocoronary artery vein-graft disease
136. Pathologic changes in aortocoronary saphenous vein grafts
137. Aspirin and dipyridamole reduced platelet deposition on prosthetic femoropopliteal grafts in man
138. In vivo quantitation of platelet deposition on human peripheral arterial bypass grafts using indium-111-labeled platelets: Effect of dipyridamole and aspirin
139. Failure of ticlopidine to inhibit deposition of indium-111-labeled platelets on Dacron prosthetic surfaces in humans
140. Platelet reactivity in human aortic grafts: A prospective, randomized midterm study of platelet adherence and release products in Dacron and polytetrafluoroethylene conduits
141. The effects of sulfinpyrazone on platelet deposition on Dacron vascular grafts in man
142. Reduction of indium-111 platelet deposition on Dacron vascular grafts in humans by aspirin plus dipyridamole
143. Platelet accumulation on mature Dacron grafts in man
144. Differentiation of Vascular prostheses in dogs with serial tests of in vivo platelet reactivity
145. Platelet survival and serotonin content after placement of arterial prostheses in dogs: Effects of neointimal coverage and high- and low-dose aspirin
146. Platelet-derived growth factor activity and mRNA expression in healing vascular grafts in baboons: Association in vivo of platelet-derived growth factor mRNA and protein with cellular proliferation
147. Published results of surgery for aortoiliac occlusive disease
148. Effects of aspirin and dipyridamole on expanded polytetrafluoroethylene graft patency
149. 111indium-platelet deposition predict patency in prosthetic arterial grafts?
150. Effect of aspirin and dipyridamole on the patency of lower extremity bypass grafts
151. Random control trial of a short course of aspirin and dipyridamole (Persantine) for femorodistal grafts
152. Antiplatelet drugs in femoropopliteal vein bypasses: A multicenter trial
153. Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs
154. Improved graft patency in patients treated with platelet-inhibiting therapy after coronary bypass surgery
155. Immediate postoperative aspirin improves vein graft patency early and late after coronary artery bypass graft surgery
156. Starting aspirin therapy after operation
157. Implications of preoperative administration of aspirin in patients undergoing coronary artery bypass grafting
158. Changing arteriosclerotic disease patterns and management strategies in lower-limb-threatening ischemia
159. Aspirin usage and its influence on femoro-popliteal vein graft patency
160. Collaborative overview of randomised trials of antiplatelet treatment: II. Maintenance of vascular graft or arterial patency by antiplatelet therapy
161. Systematic review of randomized controlled trials of aspirin and oral anticoagulants in the prevention of graft occlusion and ischemic events after infrainguinal bypass surgery
162. A prospective randomized study to examine the effect of aspirin plus dipyridamole on the patency of prosthetic femoro-popliteal grafts
163. The influence of platelet inhibition on the patency of femoro-popliteal Dacron bypass grafts
164. The efficacy of dextran-40 in preventing early postoperative thrombosis following difficult lower extremity bypass
165. The influence of anticoagulant treatment on the probability of function in femoropopliteal vein bypass surgery: Analysis of a clinical series (1970 to 1985) and interim evaluation of a controlled clinical trial
166. Aging and the anticoagulant response to warfarin therapy
167. Ischemic and hemorrhagic stroke in patients on oral anticoagulants after reconstruction for chronic lower limb ischemia
168. Influence of postoperative anticoagulant treatment on patient survival after femoropopliteal vein bypass surgery
169. Influence of coumarin treatment on patency and limb salvage after peripheral arterial reconstructive surgery
170. A decade of oral anticoagulant treatment to maintain autologous vein grafts for femoro-popliteal atherosclerosis
171. The role of auticoagulation in infrainguinal bypass surgery
172. Antithromhotic therapy for lower extremity bypass
173. Does oral anticoagulation improve patency of vein bypasses? A prospective randomized study
174. Warfarin improves outcome of infrainguinal vein bypass grafts at high risk for failure
175. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study): A randomized trial
176. Vascular smooth muscle cell proliferation: Basic investigators and new therapeutic approaches
177. Low-molecular weight heparin versus aspirin and dipyridamole after femoropopliteal bypass grafting
178. Low-molecular-weight heparin vs unfractionated heparin in femorodistal reconstructive surgery: A multicenter open randomized study
179. Low molecular mass heparin instead of unfractionated heparin during infrainguinal bypass surgery
180. Infrainguinal bypass
181. Effects of platelet-modifying drugs on arterial thromboembolism in baboons
182. Heparin and protamine use in peripheral vascular surgery: A comparison between surgeons of the Society for Vascular Surgery and the European Society for Vascular Surgery
183. Intraoperative anticoagulation in cardiovascular surgery
184. Time-related anticoagulation after regional and systemic administration of heparin in patients undergoing aortoiliac surgery
185. Systemic heparinization during peripheral vascular surgery: Thromboelastographic, activated coagulation time, and heparin titration monitoring
186. Intraoperative heparinisation, blood loss and myocardial infarction during aortic aneurysm surgery: A joint vascular research group study
187. Association of protamine IgE and IgC antibodies with life-threatening reactions to intravenous protamine
188. Evaluation of patients at risk for protamine reactions
189. Anaphylactoid reactions to protamine: An often lethal complication in insulin-depen dent diabetic patients undergoing vascular surgery
190. Protamine reversal during peripheral vascular surgery: A prospective randomized trial
191. Platelet deposition at carotid endarterectomy sites in humans
192. Effect of perioperative platelet inhibition on postcarotid endarterectomy mural thrombus formation
193. Controlled trial of aspirin in cerebral ischemia: II. Surgical group
194. Danish very-lowdose aspirin after carotid endarterectomy trial
195. Does lowdose acetylsalicylic acid prevent stroke after carotid surgery? A double-blind, placebo-controlled randomized trial
196. Drugs and surgery in the prevention of ischemic stroke
197. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: A randomised controlled trial
198. The influence of neutralizing heparin after carotid endarterectomy on postoperative stroke and wound hematoma
199. Wound hematomas after carotid endarterectomy
200. Influence of aspirin in the management of asymptomatic carotid artery stenosis
201. Adverse effects of aspirin in the treatment of asymptomatic carotid artery stenosis
202. Lack of effect of aspirin in asymptomatic patients with carotid bruits and substantial carotid narrowing
203. Restenosis or occlusion after carotid endarterectomy
204. Carotid artery stenosis following endarterectomy
205. Etiologic factors for recurrent carotid artery stenosis
206. Early restenosis after carotid endarterectomy
207. Failure of aspirin plus dipyridamole to prevent restenosis after carotid endarterectomy